Phone: (615) 327-5724

jmurray@mmc.edu

John J. Murray, M.D., Ph.D., is Associate Vice President for Research and Professor of Internal Medicine and Biomedical Sciences at Meharry Medical College, Adjunct Professor of Medicine and Pharmacology at Vanderbilt Medical School, and attending physician at Nashville General Hospital and Vanderbilt Hospital. Dr. Murray’s primary role at Meharry is to oversee the clinical research enterprise that includes supervising clinical trials, educating clinical investigators, and ensuring compliance with regulatory and ethical aspects of human research.

After graduation from Harvard College, he received doctoral degrees in Medicine and Pharmacology from Vanderbilt and was an Exchange Fellow of the National Institute of Health and the Soviet Academy of Sciences. After completing a residency and chief residency in internal medicine and a research fellowship in clinical pharmacology at Vanderbilt, he was a postdoctoral fellow in rheumatology/immunology and allergy/immunology/pulmonary medicine at Duke School of Medicine remaining on the faculty until his return to Vanderbilt holding the Elizabeth and John Murray Chair of Medicine prior to his recent roles at Meharry. In addition to being an associate editor for Lipids, Dr. Murray serves as a reviewer for such journals as the New England Journal of Medicine and the Journal of Immunology. Dr. Murray is the author of nearly 300 articles and abstracts, serves as an invited lecturer at national and international meetings, and is included in Best Doctors in America and Who’s Who in Medicine and Healthcare. In addition to his active clinical practice, he lectures, oversees research supported by the NIH, foundations and private organizations, and has directed numerous clinical trials of novel therapies in a variety of disease.

Altana Inc.  BY217/M2-111 (Murray)                                                                                       03/15/04 - 04/12/06
Effect of Roflumilast on Exacerbation Rate in Patients with Chronic Obstructive Pulmonary Disease. A 52 Week Double-Blind multicenter study with 500 mcg roflumilast once daily versus placebo

AstraZeneca SD-039-0725 (Murray)                                                                                      03/01/03 - 03/17/05
A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study of SYMBICORT pMDI Administered Once Daily in Children and Adolescents 6 to 15 Years of Age with Asthma-SPROUT

AstraZeneca   SD-004-0620 (Murray)                                                                                    10/07/02 - 07/12/05
A Placebo-Controlled Comparison of the Efficacy and Safety of the Current US Version of Pulmicort (Budesonide) Turbuhaler® and the New Version of Pulmicort Turuhaler® in Asthmatic Adults and Adolescents Currently Treated with Inhaled Steroids

AstraZeneca  SD-004-0726 (Murray)                                                                                     1/20/02 - 09/30/04
A Comparison of he Efficacy, Safety and Pharmacokinetics of the Current US Version of Pulmicort Turbuhaler® and the New Version of Pulmicort Turbuhaler® in asthmatic children

Genentech  Q2948g (Murray)                                                                                                 10/21/04 - 12/01/11
An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long Term Safety in Patients with Moderate to Severe Asthma

GlaxoSmithKline FFR100010 (Murray)                                                                                     02/25/05 - 04/14/06
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 Weeks in Pediatric Subjects Ages 1 to <12 Years with Seasonal Allergic Rhinitis

GlaxoSmithKline  FFR30002 (Murray)                                                                                      02/15/05 - 03/14/06
"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100 mcg for 4 weeks in Adult and Adolescent Subject (≥12 years of age) with Perennial Allergic Rhinitis (PAR)
Murray, John J., M.D., Ph.D. (Continued)

GlaxoSmithKline MHE 100185 (Murray)                                                                                   07/22/04 - 05/11/06
A Mulitcenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study to Evaluate Corticosteroid-Reduction and Sparing Effects of Mepolizumab 750 mg Intravenous in Subjects with Hypereosinophilic Syndromes (HES), and to Evaluate the Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of HES over Nine Months

GlaxoSmithKline  MHE100901 (Murray)                                                                                   03/07/05 - 11/28/07
An Open Label Extension Study to Study 100185, to Evaluate Long-Term Safety, Efficacy and Optimal Dosing Frequency of  750mg Intravenous Mepolizumab in Subjects with Hypereosinophilic Syndrome

Merck:  (Murray)                                                                                                                      01/08/04 – 10/30/04
A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to E valuate the Clinical Effect of Oral Montelukast Versus Placebo During the Allergy Season in Patients with Seasonal Aeroallergen Sensitivity and Chronic Asthma which is also Active During Allergy Season.   Protocol No. 289/SNG554.  Principal Investigator.   2004.

GlaxoSmithKline SFA100062 (Murray)                                                                                    01/15/05 - 01/14/06
A Randomized-Parllel Group, Double-Blind, Comparative Trial Assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 Years of Age, with Persistent Asthma, Who Have Either a B16-Arg/Arg, a B16-Gly/Gly or a B-16 Arg/Gly Genotype and are Treated with Fluticasone Propionate/Salmeterold DISKUS® Combination Product 100/50mct of Salmeterol DISKUS® 50mcg BID

GlaxoSmithKline  SFA100316 (Murray)                                                                                   12/17/03 - 01/01/06
A Stratified, Multicenter, Randomized, Double-Blind paralled B Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects with Activity-Induced Bronchospasm

King Pharmaceuticals  MRE0470-203 (Murray)                                                                       11/01/03 - 10/26/05
Two-Part Study to Evaluate the Safety of Binodenoson (MRE0470) in Adult Subjects with Mild, Intermittent Asthma

Novartis  IGE025AIA05 (Murray)                                                                                             02/14/05 - 12/14/06
A 1 Year, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter evaluation of Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of omalizumab in children (6-<12years) with moderate-severe, persistent, inadequately controlled allergic asthma

GSK   SFA103153 (Murray)                                                                                                    03/01/05 - 02/28/06
A Multicenter, Randomized, Double-Blind, Parallel Group, 52 Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS BID or Fluticasone Propionate 100mcg DISKUS BID alone

Pfizer/ Quintiles   WA18063RG; WA18063B (Tanner)                                                            08/10/05 - 04/10/07
A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy

Pfizer (Murray)                                                                                                                        04/30/05 – 05/01/06
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Six Week Study of the Efficacy and Safety of Tofimilast Dry Powder for Inhalation in Adults with Persistent Asthma. 

Pfizer/Aventis  (Murray)                                                                                                          06/01/03 – 9/30/06                       
Efficacy and Safety of Inhaled Human Insulin (Exubera®) Compared with Subcutaneous Human Insulin in the Therapy of Adult Subjects with Type 1 or Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial.